Table 2.
Major hospital outcomes for the study sample overall and by the presence of infection sub-types
| Outcome | Overall (n = 1112) |
No infection on admission (n = 894) |
Infection on admission (n = 218) |
p value infection on admission versus no infection on admission | No nosocomial infection (n = 1065) |
Nosocomial infection (n = 47) |
p value nosocomial infection versus no nosocomial infection | Antibiotic-susceptible infection(s) only (n = 73) |
At least one antibiotic-resistant infection (n = 44) |
p value (antibiotic susceptible vs resistant) |
|---|---|---|---|---|---|---|---|---|---|---|
| In-hospital mortality, n (%) | 64 (6%) | 39 (4%) | 25 (12%) | < 0.001 | 48 (5%) | 16 (34%) | < 0.001 | 10 (14%) | 5 (11%) | 0.94 |
| North American Consortium for End-Stage Liver Disease-acute-on-chronic liver failure, n (%) | 35 (3%) | 14 (2%) | 21 (10%) | < 0.001 | 25 (2%) | 10 (21%) | < 0.001 | 12 (16%) | 2 (5%) | 0.10 |
| Intensive care unit admission, n (%) | 221 (20%) | 160 (18%) | 61 (28%) | 0.001 | 188 (18%) | 33 (70%) | < 0.001 | 35 (48%) | 12 (27%) | 0.04 |
| Length of stay (days) | 4 (4) | 3 (7.75) | 6 (3) | < 0.001 | 3 (4) | 14 (12.5) | < 0.001 | 8 (9) | 7 (6.3) | 0.24 |
| 30-day mortality, n (%) | 80/986 (8%) | 52/764 (7%) | 28/204 (14%) | 0.002 | 67/928 (7%) | 13/40 (33%) | < 0.001 | 11/68 (16%) | 6/41 (15%) | 0.83 |
| 30-day readmission, n (%) | 196/986 (20%) | 150/764 (20%) | 46/204 (23%) | 0.4 | 189/928 (21%) | 7/40 (18%) | 0.84 | 15/68 (22%) | 9/41 (22%) | 0.99 |
Median (interquartile range) for continuous parameters; frequency (%) for categorical parameters
Bold values indicate statistically significant associations (p < 0.05 after adjustment for multiple comparisons via Benjamini–Hochberg method)